share_log
Moomoo 24/7 ·  Apr 11 07:20
Oncolytics Biotech Has Submitted Type C Meeting Request To FDA For Q2 2024 To Discuss The Company's Planned Registration-enabling Trial For Pelareorep In HR+/HER2- Metastatic Breast Cancer
Disclaimer: This content is for informational and educational purposes only and does not constitute a recommendation or endorsement of any specific investment or investment strategy. Read more
    Write a comment